Get to know us
We started as Cam346. Ltd in London (UK). With Brexit, we transferred as Triquetra Medicines to Sweden in 2019. It took us several years and iterations to develop our unique R&D sourcing, business, and patient support model. We continue to overcome industry prejudices, dogmas, and dominant paradigms. Every single day, we apply our expertise, experiences, ingenuity, and drive to turn our visions into reality.
Our team
Our strength lies in our individuality, diverse international backgrounds and locations, and almost 70 years of combined experience in the pharmaceutical and diagnostics industry across the entire R&D value chain.
For good reasons, we were, are and always will be a majority women-led company.
Katerina Chinenyeze
Co-Founder, COO and Operational Lead
An experienced Patient Safety scientist, with background in Biomedical and Cognitive Sciences, >13 years in the pharmaceutical industry.
A high-energy, natural leader, generalist problem-solver and organizer with an eye for the bigger picture and spirit for innovation and creativity.
Steffen Ernst
Co-Founder, CEO and CMO
Successful entrepreneur, licensed physician, Board-certified Toxicologist, Patient Safety expert and MBA with >25 years Big Pharma industry experience across the entire pre-clinical and clinical value chain.
A safety-focused, people and organisational developer and creative, visionary leader.
Helge Lubenow
Co-Founder/CFO and BD Lead
A Biologist and geneticist with extensive strategic Business Development and entrepreneurial leadership experience in pharmaceuticals and diagnostics.
A superb, visionary, and indispensable facilitator between Science, Business Development, and Finance.
PD. Dr. Antje Wick
Head of the Heidelberg University Hospital Headache Clinic in Germany and attending Neurooncologist, Dep. of Neurooncology, Neurology Clinic, and National Center for Tumor Diseases Heidelberg, Germany.
Dr. Wick is a broadly interested, open-minded clinical headache and brain tumor expert providing independent medical expertise and counsel to the development of TRQ001.”
Dr. Jenny Royle
Rekaryo, Kenilworth and MediPaCe Ltd, London, United Kingdom.
Dr. Royle is a Cambridge University PhD graduate in Pharmacology and a post-graduate qualification in Psychology and Behaviour Change with a long pharma industry career in Clinical Development, Clinical Sciences, Regulatory Affairs, and Patient Safety before founding Rekaryo and MediPaCe Ltd. Dr. Royle is a devoted and engaged expert of Public Health development and patient advocate operating at the interface between patients, hospitals, charities, academia, and pharma industry. She is providing counsel and expertise to the development of TRQ001.
Dr. Peter-Christoph Schulz
Senior Vice President, Pharmacovigilance and Quality at EXPLIC8, Luzern, Switzerland.
An almost too-good-to-be-true drug and Patient Safety expert with an invaluable, competent, and critical mind dervived from >25 years of hands-on experience in the pharmaceutical industry. He is primarily supporting the development of TRQ001.
Our invaluable Advisors (Scientifc Advisory Board)
Dominik Aue CFA
Let's face it - no start-up can survive without competent external financial counsel nowadays.
We are exceedingly lucky to work with Dominik, a Swiss financial expert with over 12 years experience. His creative and innovative approaches, derived from a number of successful start-ups he supported, are an invaluable part of our company and strategy.
